Swiss speciality chemicals company Clariant is set to demonstrate the ‘future-proofing’ capabilities of its Mevopur and Remafin-EP products for pharmaceutical packaging and drug-delivery devices.

The demonstration will be carried out at the MD&M West exhibition ahead of the new US Pharmacopeia (USP) regulations.

Clariant North America medical and pharmaceutical manager Eric Rohr said that the company has already completed USP-compliance testing for pigment and additive ingredients in its Mevopur and Remafin-EP product ranges for pharmaceutical packaging applications.

“The Bormed service package, based on Borealis’ commitment, service and compliance to the healthcare industry, complements Clariant’s Mevopur promise for medical devices and packaging.”

With the completion of the tests, the company has opened new options for manufacturers who intend to change their drug packaging.

Clariant has also been selected as a distributor of Austria-based firm Borealis’ Bormed solutions of dedicated healthcare polyolefins.

Under the agreement, Clariant will be able to sell the complete Bormed portfolio of homopolymer and random copolymer polypropylene (PP), in addition to high-density polyethylene (HDPE) and Low-density polyethylene (LDPE) resins.

The company can also provide Bormed resins as ‘ready-to-use’ Mevopur compounds.

Bormed solutions are used for a wide range of medical devices, diagnostics and pharmaceutical packaging, including syringes, inhalers, intravenous (IV) bags dialysis filters, pipette tips, and packaging such as bottles and blow-fill seal (BFS) vials.

Rohr said: “The Bormed service package, based on Borealis’ commitment, service and compliance to the healthcare industry, complements Clariant’s Mevopur promise for medical devices and packaging.

“They are change-controlled, produced to consistently high standards, and tested for assured compliance with relevant European and US Pharmacopeia and ISO standards.”